YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Dicerna IPO Proves Investor Interest in RNAi


February 3, 2014 | Dicerna Pharmaceuticals, based in Watertown, MA, pulled in $90 million last week in its initial public offering. Dicerna is working on RNA interference-based therapies, beginning with indications for liver disease, various cancers, and primary hyperoxaluria, a genetic disease that can lead to kidney failure – all currently in preclinical phases. Dicerna's share price rose over 200% over the course of the day, the largest first-day gain for any company since 2005, demonstrating an appetite for gene silencing technologies among investors. Boston Globe
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.